Management of Thromboembolism in Hematologic Malignancies

ABSTRACT

Patients with hematologic malignancies have increased risks of thromboembolism or bleeding. The commonest thrombotic complication is venous thromboembolism (VTE). Other thrombotic conditions occur in association with specific disorders, such as thrombotic thrombocytopenic purpura in hematopoietic stem cell transplantation and disseminated intravascular coagulation in acute promyelocytic leukemia. Clinical trials show that unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are efficacious for VTE prophylaxis in cancer patients after major surgery or when hospitalized for acute medical illnesses. These findings in cancer patients are probably applicable to patients with hematologic malignancies, in whom there are very few studies. However, the effectiveness of anticoagulant VTE prophylaxis is not established in ambulatory patients with cancer except for multiple myeloma patients treated with thalidomide and chemotherapy. LMWH is widely used as initial treatment for VTE because it enables home therapy without laboratory monitoring, thereby improving the patient's quality of life. UFH is preferred in patients with high bleeding risks and renal impairment. In cancer patients, vitamin K antagonists for the long-term treatment of VTE are increasingly replaced by LMWH, which show superior efficacy. When prescribing anticoagulant prophylaxis or treatment to patients with hematologic malignancies, clinical benefits must be weighed carefully against the risks of bleeding.

KEYWORDS

Thromboembolism - hematologic malignancy - heparin - coumadin

REFERENCES

• 1 Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris.  The New Sydenham Society. 1865;  3 94-99
• 2 Ottinger H, Belka C, Kozole G et al.. Deep venous thrombosis and pulmonary artery embolism in high-grade non-Hodgkin's lymphoma: incidence, causes and prognostic relevance.  Eur J Haematol. 1995;  54 186-194
• 3 Gugliotta L, Mazzucconi M G, Leone G et al.. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group.  Eur J Haematol. 1992;  49 63-66
• 4 Zangari M, Barlogie B, Anaissie E et al.. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.  Br J Haematol. 2004;  126 715-721
• 5 Zangari M, Anaissie E, Barlogie B et al.. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.  Blood. 2001;  98 1614-1615
• 6 Mitchell L G, Andrew M, Hanna K et al.. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PARKAA study.  Thromb Haemost. 2003;  90 235-244
• 7 Athale U H, Chan A KC. Thrombosis in children with acute lymphoblastic leukemia Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia; effects of the disease and therapy.  Thromb Res. 2003;  111 199-212
• 8 Sanz M A, Tallman M S, Le-Coco F. Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemia.  Oncologist. 2005;  10 806-814
• 9 Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia.  Blood. 1998;  91 3093-3102
• 10 Uderzo C, Fumagalli M, de Lorenzo P et al.. Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation.  Bone Marrow Transplant. 2000;  26 1005-1009
• 11 Alessandrino E P, Martinelli G, Canevari A et al.. Prompt response to high-dose intravenous immunoglobulins given as first-line therapy in post-transplant thrombotic thrombocytopenic purpura.  Bone Marrow Transplant. 2000;  25 1217-1218
• 12 Rosovsky R P, Kuter D J. Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management.  Hematol Oncol Clin North Am. 2005;  19 183-202
• 13 De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms.  Crit Rev Oncol Hematol. 2004;  50 187-196
• 14 Falanga A, Gordon S G. Isolation and characterisation of cancer procoagulant: a cysteine proteinase from malignant tissue.  Biochemistry. 1985;  24 5558-5567
• 15 Falanga A, Consonni R, Marchetti M et al.. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by retinoic acid.  Leukemia. 1994;  8 156-159
• 16 Rickles F R, Falanga A. Molecular basis for the relationship between thrombosis and cancer.  Thromb Res. 2001;  102 V215-V224
• 17 Morel O, Toti F, Hugel B, Freyssinet J M. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors.  Curr Opin Hematol. 2004;  11 156-164
• 18 Sase T, Wada H, Yamaguchi M et al.. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma.  Thromb Haemost. 2005;  93 153-159
• 19 Dixit A, Kannan M, Mahapatra M, Choudhry V P, Saxena R. Roles of protein C, protein S, and antithrombin III in acute leukemia.  Am J Hematol. 2006;  81 171-174
• 20 Athale U H, Chan A KC. Thrombosis in children with acute lymphoblastic leukemia Part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia.  Thromb Res. 2003;  111 125-131
• 21 Athale U H, Siciliano S A, Crowther M, Barr R D, Chan A K. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.  Br J Haematol. 2005;  129 803-810
• 22 Barbui T, Falanga A. Thalidomide and thrombosis in multiple myeloma.  J Thromb Haemost. 2003;  1 421-422
• 23 Nowak-Gottl U, Heinecke A, von Kries R et al.. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.  Thromb Res. 2001;  103 165-172
• 24 Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).  Thromb Haemost. 2000;  83 840-843
• 25 Mitchell L G, Hoogendoorn H, Giles P V, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced anti-thrombin III deficiency.  Blood. 1994;  83 386-391
• 26 Mitchell L G, Sutor A N, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia; coagulopathy induced by disease and treatment.  Semin Thromb Hemost. 1995;  21 390-401
• 27 Semeraro N, Montemurro P, Giordano P et al.. Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukemia.  Thromb Haemost. 1990;  64 38-40
• 28 Andrew M, Brooker L, Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukemia.  Blood Coagul Fibrinolysis. 1994;  5 S24-S36
• 29 Zaunschirm A, Muntean W. Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia.  Pediatr Hematol Oncol. 1986;  3 19-25
• 30 Halton J M, Mitchell L G, Vegh P A, Eves M, Andrew M A. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase.  Am J Hematol. 1994;  47 157-161
• 31 Nowak Gottl U, Rath B, Binder M et al.. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiency during ALL induction therapy.  Haematologica. 1995;  80 451-453
• 32 Nowak Gottl U, Kuhn N, Wolff J EA et al.. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase treated children.  Eur J Haematol. 1996;  56 35-38
• 33 Nowak Gottl U, Weberr G, Ziemann D, Ahlke E, Boos J. Influence of two different E coli asparaginase preparations of fibrinolytic proteins in childhood ALL.  Haematologica. 1996;  81 127-131
• 34 Nowak-Gottl U, Ahlke E, Klosel K, Jurgens H, Boos J. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukemia re-induction therapy using three different asparaginase preparations.  Eur J Pediatr. 1997;  156 848-850
• 35 Duval M, Suciu S, Ferster A et al.. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organization for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.  Blood. 2002;  99 2734-2739
• 36 Isacson S. The effect of prednisolone on the coagulation and fibrinolytic system.  Scand J Haematol. 1970;  7 212-216
• 37 Patrassi G M, Sartori M T, Riggotti P et al.. Reduced fibrinolytic potential one year after kidney transplantation: relationship to long term steroid therapy.  Transplantation. 1995;  59 1416-1420
• 38 Sutor A H, Niemeyer C, Sauter S et al.. Corticosteroids cause multiple changes of coagulation factors.  Ann Hematol. 1992;  4 A83
• 39 Ozturk G, Ozsoylu S, Muriel T. Effects of methylprednisolone on FVIII:c and vWF levels.  Eur J Haematol. 1994;  53 119-120
• 40 Scarpace S L, Hahn T, Roy H et al.. Arterial thrombosis in four patients treated with thalidomide.  Leuk Lymphoma. 2005;  46 239-242
• 41 Osman K, Comenzo R, Rajkumar S V. Deep vein thrombosis and thalidomide therapy for multiple myeloma.  N Engl J Med. 2001;  344 1951-1952
• 42 Dimopoulos M A, Anagnostopoulos A, Terpos E et al.. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.  Haematologica. 2006;  91 252-254
• 43 Groopman J, Ellman J. Acute promyelocytic leukemia.  Am J Hematol. 1979;  7 395-408
• 44 Tallman M S, Kwaan H C. Reasssessing the hemostatic disorder associated with acute promyelocytic leukemia.  Blood. 1992;  79 543-553
• 45 Beuer K A, Conway E M, Bach R et al.. Tissue factor gene expression in acute myeloblastic leukemia.  Thromb Res. 1989;  56 425-430
• 46 Beuer K A, Rosenberg R D. Thrombin generation in acute promyelocytic leukemia.  Blood. 1984;  64 791-796
• 47 Myers T J, Rickles F R, Barb C, Cronlund M. Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity.  Blood. 1981;  57 518-525
• 48 Falanga A, Iacoviello L, Evangelista V et al.. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia given all-trans-retinoic acid.  Blood. 1995;  86 1072-1081
• 49 Bennett B, Booth A, Croll A, Dawson A A. The bleeding disorder in acute promyelocytic leukemia: fibrinolysis is due to u-PA rather than defibrination.  Br J Haematol. 1989;  71 511-517
• 50 Dombret H, Scrobohaci M L, Ghorra P et al.. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment.  Leukemia. 1993;  7 2-9
• 51 Gralnick H R, Abrell E. Studies on the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia.  Br J Haematol. 1973;  24 89-99
• 52 Speiser W, Pabinger-Fasching I, Kyrle P A et al.. Hemostatic and fibrinolytic parameters in patients with acute myeloid leukemia: activation of blood coagulation, fibrinolysis and unspecific proteolysis.  Blut. 1990;  61 298-302
• 53 Tallman M S, Andersen J W, Schiffer C A et al.. All-trans retinoic acid in acute promyelocytic leukemia.  N Engl J Med. 1997;  337 1021-1028
• 54 Mandelli F, Diverio D, Avvvisati G et al.. Molecular remission in PML/RaRalpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy.  Blood. 1997;  90 1014-1021
• 55 Runde V, Aul C, Heyll A, Schneider W. All-trans retinoic acid: not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia.  Blood. 1992;  79 534-535
• 56 Escudier S M, Kantarjian H M, Estey E H. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.  Leuk Lymphoma. 1996;  20 435-439
• 57 Spruce W E, Forman S J, Blume K G et al.. Hemolytic uremic syndrome after bone marrow transplantation.  Acta Haematol. 1982;  67 206-210
• 58 Kondo M, Kojima S, Horibe K et al.. Hemolytic uremic syndrome after allogenic or autologous hemapoietic stem cell transplantation for childhood malignancies.  Bone Marrow Transplant. 1998;  21 281-286
• 59 Pettitt A R, Clark R E. Thrombotic microangiopathy following bone marrow transplantation.  Bone Marrow Transplant. 1994;  14 495-504
• 60 Natazuka T, Kajimoto K, Ogawa R et al.. Coagulation abnormalities and thrombotic microangiopathy following bone marrow transplantation from HLA-matched unrelated donors in patients with hematological malignancies.  Bone Marrow Transplant. 1998;  21 815-819
• 61 Moake J L, Rudy C K, Troll J H. Unusually large plasma factor VIII von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1436
• 62 Chong B H, Murray B, Berndt M C et al.. Plasma P-selectin is increased in thrombotic consumptive platelet disorders.  Blood. 1994;  83 1535-1541
• 63 Tsai H M. Molecular mechanisms in thrombotic thrombocytopenic purpura.  Semin Thromb Hemost. 2004;  30 549-557
• 64 Kentouche K, Zintl F, Angerhaus D et al.. von Willebrand factor-cleaved protease (ADAMTS13) in the course of stem cell transplantation.  Semin Thromb Hemost. 2006;  32 98-104
• 65 Wada H, Kaneko T, Ohiwa M et al.. Plasma cytokine levels in thrombotic thrombocytopenic purpura.  Am J Hematol. 1992;  40 167-170
• 66 Holler E, Kolb J H, Hiller F et al.. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-vs-host-disease after HLA-identical bone marrow transplantation.  Blood. 1989;  73 2018-2024
• 67 Sarode R, McFarland J C, Flomemberg N et al.. Therapeutic plasma exchange does not appear to be effective in the management of TTP and hemolytic uremic syndrome following bone marrow transplantation.  Bone Marrow Transplant. 1995;  16 271-275
• 68 Hamblin N, Powles R, Treleaven J et al.. Defibrotide for refractory thrombotic thrombocytopenic purpura after bone marrow transplantation.  Blood. 1996;  88 2966 , (abst)
• 69 Bayik M M, Akoglu T, Tuglular T F et al.. Treatment of TTP with defibrotide.  Am J Hematol. 1993;  43 74-75
• 70 Nosari A, Muti G, Busnach G et al.. Intravenous gamma globulin in refractory thrombotic thrombocytopenic purpura.  Acta Haematol. 1996;  96 255-257
• 71 Mohren M, Markmann I, Jentsch-Ullrich K et al.. Increased risk of venous thromboembolism in patients with acute leukaemia.  Br J Cancer. 2006;  94 200-202
• 72 King M M, Rasnake M S, Rodriguez R G, Riley N J, Stamm J A. Peripherally inserted central venous catheter-associated thrombosis: retrospective analysis of clinical risk factors in adult patients.  South Med J. 2006;  99 1073-1077
• 73 Monreal M, Zotz R B, Decousus H et al.. Influence of perceived risk factors for bleeding on venous thromboembolism prophylaxis practices in acutely ill medical patients: findings from IMPROVE.  Blood. 2005;  106 269A , (abst)
• 74 Decousus H, Zotz R B, Tapson V F et al.. Factors at admission that are predictive of increased in-hospital bleeding in acutely ill medical patients: findings from the international medical prevention registry on venous thromboembolism (IMPROVE).  Blood. 2005;  106 81 , (abst)
• 75 Geerts W H, Pineo G F, Heit J A et al.. Prevention of venous thromboembolism.  Chest. 2004;  126 338S-400S
• 76 Nicolaides A, Irving D, Pretzell M et al.. The risk of deep-vein thrombosis in surgical patients.  Br J Surg. 1973;  60 312
• 77 Flordal P A, Bergqvist D, Burmark U S et al.. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations.  Eur J Surg. 1996;  162 783-789
• 78 Enoxacan Study Group . Efficacy and safety of a low-molecular weight heparin and standard unfractionated heparin for prophylaxis of post-operative venous thromboembolism: European multicenter trial.  World J Surg. 1997;  21 2-8
• 79 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery.  N Engl J Med. 1988;  318 1162-1173
• 80 Clagett G P, Reisch J S. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis.  Ann Surg. 1988;  208 227-240
• 81 Mismetti P, Laporte S, Darmon J Y, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.  Br J Surg. 2001;  88 913-930
• 82 Bergqvist D, Burmark U S, Flordal P A et al.. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 units in 2070 patients.  Br J Surg. 1995;  82 496-501
• 83 Wicky J, Couson F, Ambrosetti P et al.. Postoperative deep venous thrombosis (DVT) and low-molecular weight heparin (LMWH) type and dosage.  Thromb Haemost. 1993;  69 402-403
• 84 Wiig J N, Solhaug J H, Bilberg T et al.. Prophylaxis of venographically diagnosed deep vein thrombosis in gastro-intestinal surgery: multicentre trials 20mg and 40mg enoxaparin versus dextran.  Eur J Surg. 1995;  161 663-668
• 85 McLeod R S, Geerts W H, Sniderman K W et al.. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial.  Ann Surg. 2001;  233 438-444
• 86 Bjerkeset O, Larsen S, Reiertsen O. Evaluation of enoxaparin given before and after operation to prevent venous thromboembolism during digestive surgery: play-the-winner designed study.  World J Surg. 1997;  21 584-588
• 87 Bergqvist D, Agnelli G, Cohen A T et al.. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.  N Engl J Med. 2002;  346 975-980
• 88 Rasmussen M S. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis.  Cancer Treat Rev. 2002;  28 141-144
• 89 Rasmussen M S, Jorgensen L N, Willie-Jorgensen P et al.. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complication in patients undergoing major abdominal surgery: a multicenter randomised open-label study.  J Thromb Haemost. 2006;  4 2384-2390
• 90 Nicolaides A, Fareed J, Kakkar A K et al.. Prevention and treatment of venous thromboembolism: International consensus statement.  Int Angiol. 2006;  25 101-161
• 91 Agnelli G, Bergqvist D, Cohen A, Gallus A, Gent M. for the PEGASUS investigators . Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk sbdominal surgery.  Br J Surg. 2005;  92 1212-1220
• 92 Levine M, Hirsh J, Gent M et al.. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer.  Lancet. 1994;  343 886-889
• 93 Samama M M, Cohen A T, Darmon J Y et al.. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.  N Engl J Med. 1999;  341 793-800
• 94 Liezorovicz A, Cohen A T, Turpie A GG et al.. A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study.  Thromb Haemost. 2003;  1(suppl) OC396 , (abst)
• 95 Cohen A T, Davidson B L, Gallus A S et al.. ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patient: randomized placebo controlled trial.  BMJ. 2006;  332 325-329
• 96 Chong B H, Kakkar A K, Tapson V F et al.. Venous thromboembolism prophylaxis practices in acutely ill medical patients with either previous cancer or currently active cancer: findings from IMPROVE.  Blood. 2004;  104 490A , (abst)
• 97 Hutten B A, Prins M H, Gent M et al.. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.  J Clin Oncol. 2000;  18 3078-3083
• 98 Koopman M M, Prandoni P, Piovella F et al.. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home.  N Engl J Med. 1996;  334 682-687
• 99 Columbus Investigators . Low-molecular weight heparin in the treatment of patients with venous thromboembolism.  N Engl J Med. 1997;  337 657-662
• 100 Palareti G, Legnani C, Lee A et al.. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy.  Thromb Haemost. 2000;  84 805-810
• 101 Prandoni P, Lensing A W, Picciolo A et al.. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.  Blood. 2002;  100 3484-3488
• 102 Prandoni P. How I treat venous thromboembolism in patients with cancer.  Blood. 2005;  106 4027-4033
• 103 Levine M, Gent M, Hirsh J et al.. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  N Engl J Med. 1996;  334 677-681
• 104 Kakkar A K, Levine M, Pinedo H M, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey.  Oncologist. 2003;  8 381-388
• 105 Ageno W, Steidl L, Marchesi C et al.. Selecting patients for home treatment of deep vein thrombosis: the problem of cancer.  Haematologica. 2002;  87 286-291
• 106 Chong B H, Brighton T A, Baker R, Thurlow P, Lee C H. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.  J Thromb Thrombolysis. 2005;  19 173-181
• 107 Merli G, Spiro T E, Olsson C G et al.. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.  Ann Intern Med. 2001;  134 191-202
• 108 Simmoneau G, Sors H, Charbonnier B et al.. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group.  N Engl J Med. 1997;  337 663-669
• 109 Kovacs M J, Anderson D, Morrow B et al.. Outpatient treatment of pulmonary embolism with dalteparin.  Thromb Haemost. 2000;  83 209-211
• 110 Buller H R, Davidson B L, Decousus H et al.. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.  Ann Intern Med. 2004;  140 867-873
• 111 Buller H R, Davidson B L, Decousus J et al.. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.  N Engl J Med. 2003;  349 1695-1702
• 112 Marwan S, Akashes M S, Abu-Hajir M M. The safety of enoxaparin in patients older than 60 years with APL AML or high risk MDS undergoing induction or consolidation chemotherapy.  Blood. 1999;  94 225 , (abst 4211)
• 113 Imberti D, Vallisa D, Anselmi E et al.. Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia.  Tumori. 2004;  90 390-393
• 114 Schimmer A D, Stewart A K, Keating A et al.. Safety of therapeutic anticoagulation in patients with multiple myeloma receiving autologous stem cell transplantation.  Bone Marrow Transplant. 1998;  22 491-494
• 115 Levine M N, Lee A YY, Kakkar A K et al.. Cancer and thrombosis. In: Colman RC, Marder VJ, Clowes AW, George JN, Goldhaber SZ Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia; Lippincott Williams & Wilkins 2006: 1251-1262
• 116 Decousus H, Leizorovicz A, Parent F et al.. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.  N Engl J Med. 1998;  338 409-415
• 117 Millward S F, Oliva V L, Bell S D et al.. Gunther tulip retrievable vena cava filter: results from the registry of the Canadian Interventional Radiology Association.  J Vasc Interv Radiol. 2001;  12 1053-1058
• 118 Meyer G, Marjanovic Z, Valcke J et al.. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.  Arch Intern Med. 2002;  162 1729-1735
• 119 Lee A Y, Levine M N, Baker R I et al.. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  N Engl J Med. 2003;  349 146-153
• 120 Scarpace S I, Hahn T, Roy H et al.. Arterial thrombosis in four patients treated with thalidomide.  Leuk Lymphoma. 2005;  46 239-242